ENGLEWOOD, Colo., Jan. 11, 2024 /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company” or “Ampio”), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced…
Ampio Provides Litigation Update – Reports Settlement in Principle of Certain Pending Legal Actions
This post was originally published on this site